Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis. It is also developing SEL-403 product candidate, a combination therapy comprising SVP-rapamycin and LMB-100, which is in Phase I clinical trial for the treatment of patients with malignant pleural or peritoneal mesothelioma; and SELA-070, a nicotine vaccine product candidate that is in Phase I clinical trial for smoking cessation and relapse prevention. In addition, the company engages in the development of gene therapy product candidates that are in preclinical development for rare inborn errors of metabolism, including SEL-302, a lead gene therapy program for the treatment methylmalonic academia; and SEL-313, a gene therapy product candidate to treat ornithine transcarbamylase deficiency. Selecta Biosciences, Inc. has license and collaboration agreements with Spark Therapeutics, Massachusetts Institute of Technology, Shenyang Sunshine Pharmaceutical Co., Ltd., BIND Therapeutics, Inc., and Massachusetts Eye and Ear Infirmary, as well as research collaboration agreements with National Cancer Institute. The company was founded in 2007 and is headquartered in Watertown, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-923-1400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$900,000.00
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/8/2019 (Estimated)
OptionableOptionable
Selecta Biosciences (NASDAQ:SELB) Frequently Asked Questions
What is Selecta Biosciences' stock symbol?
Selecta Biosciences trades on the NASDAQ under the ticker symbol "SELB."
How were Selecta Biosciences' earnings last quarter?
Selecta Biosciences Inc (NASDAQ:SELB) posted its earnings results on Friday, March, 15th. The company reported ($0.65) earnings per share for the quarter, topping analysts' consensus estimates of ($0.75) by $0.10. The business earned $0.90 million during the quarter. View Selecta Biosciences' Earnings History.
When is Selecta Biosciences' next earnings date?
What price target have analysts set for SELB?
6 brokerages have issued 12-month target prices for Selecta Biosciences' stock. Their predictions range from $4.00 to $33.00. On average, they expect Selecta Biosciences' stock price to reach $12.50 in the next year. This suggests a possible upside of 384.5% from the stock's current price. View Analyst Price Targets for Selecta Biosciences.
What is the consensus analysts' recommendation for Selecta Biosciences?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Selecta Biosciences in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Selecta Biosciences.
What are Wall Street analysts saying about Selecta Biosciences stock?
Here are some recent quotes from research analysts about Selecta Biosciences stock:
- 1. Stifel Nicolaus analysts commented, "We are reiterating our Buy rating and $7 target price after SELB reported its 4Q18 financial and business update. While we believe SELB’s 1Q19 capital raise addressed some of the near-term headwinds for the stock and should allow the company to further develop its lead program, SEL-212, as a treatment for chronic severe gout, we do think the company must execute well in order to achieve its communicated timelines, which appear somewhat aggressive. As we published recently, the design of the H2H study (SEL-212 vs. Krystexxa) and the fact Krystexxa is being used as monotherapy may not fully resolve the investor debate around SEL-212’s commercial opportunity, even if results are positive. With that said, we remain encouraged after our discussion with management today in which it indicated securing a partnership for its ImmTOR platform remains a priority this year." (3/15/2019)
- 2. According to Zacks Investment Research, "Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States. " (1/10/2019)
- 3. Mizuho analysts commented, "We hosted a doc call on 10/29 to discuss SEL-212. Our consultant noted some of the main potential advantages of SEL-212 vs. the standard of care including; 1) Improved treatment regimen with fewer infusions (1x/month) vs. a proposed Krystexxa combo (2x/month + daily or weekly anti-proliferative agent) and 2) Superior safety profile. Our consultant believes SEL-212 is ready for phase 3 given considerable amounts of data generated to date on treatment regimen and dosing along with clear objective measurements showing tophi mitigation and lowering of uric acid levels in a majority of patients. She argued that had the stopping rules not been as stringent in the phase 2 trial, the results may have looked better." (11/5/2018)
- 4. Canaccord Genuity analysts commented, "We expect Selecta to present positive 5-dose Phase 2 combination data for SEL-212 in severe gout during 3Q18, and see significant upside for the stock. Selecta is likely to present data from multiple dosing cohorts, with up to n=20 patients from each cohort. We suspect focus will be on the 0.15 mg/kg SVP-rapamycin + 0.20 pegsiticase dose, but await upcoming data. We see little reason that SEL-212 will not reproduce data at 5 months similar to that seen at 3 months, where ~80% Serum Uric Acid control was shown." (7/11/2018)
Has Selecta Biosciences been receiving favorable news coverage?
News stories about SELB stock have been trending negative on Thursday, according to InfoTrie. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Selecta Biosciences earned a media sentiment score of -2.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
Are investors shorting Selecta Biosciences?
Selecta Biosciences saw a decrease in short interest during the month of February. As of February 15th, there was short interest totalling 580,401 shares, a decrease of 47.3% from the January 31st total of 1,102,249 shares. Based on an average trading volume of 434,194 shares, the short-interest ratio is currently 1.3 days. Currently, 1.7% of the shares of the stock are short sold. View Selecta Biosciences' Current Options Chain.
Who are some of Selecta Biosciences' key competitors?
Some companies that are related to Selecta Biosciences include Kamada (KMDA), Aeglea Bio Therapeutics (AGLE), Acer Therapeutics (ACER), Tyme Technologies (TYME), Athersys (ATHX), Galectin Therapeutics (GALT), Spero Therapeutics (SPRO), Intec Pharma (NTEC), CELYAD SA/ADR (CYAD), Poxel (PXXLF), MEI Pharma (MEIP), Adamas Pharmaceuticals (ADMS), Mersana Therapeutics (MRSN), Aldeyra Therapeutics (ALDX) and Proteostasis Therapeutics (PTI).
What other stocks do shareholders of Selecta Biosciences own?
Who are Selecta Biosciences' key executives?
Selecta Biosciences' management team includes the folowing people:
- Dr. Omid C. Farokhzad, Co-Founder, Chairman & Member of the Scientific Advisory Board (Age 50)
- Dr. John H. Leaman, CFO, Head of Corp. Strategy & Treasurer (Age 46)
- Dr. Lloyd Johnston, COO and Sr. VP of R&D (Age 51)
- Dr. Werner Cautreels, Advisor (Age 67)
- Dr. Carsten Brunn, CEO, Pres & Director (Age 48)
When did Selecta Biosciences IPO?
(SELB) raised $64 million in an initial public offering on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. UBS Investment Bank and Stifel served as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers.
Who are Selecta Biosciences' major shareholders?
Selecta Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Orbimed Advisors LLC (7.03%), Artal Group S.A. (2.67%), FMR LLC (1.54%), Two Sigma Investments LP (0.89%), Geode Capital Management LLC (0.78%) and Geode Capital Management LLC (0.78%). Company insiders that own Selecta Biosciences stock include Amir Nashat, David Siewers, Earl Sands, Edwin M Kania, Jr, Lloyd P Johnston, Peter Keller, Timothy A Springer, Timothy C Barabe and Werner Cautreels. View Institutional Ownership Trends for Selecta Biosciences.
Which major investors are selling Selecta Biosciences stock?
Which major investors are buying Selecta Biosciences stock?
SELB stock was acquired by a variety of institutional investors in the last quarter, including Fosun International Ltd, Two Sigma Investments LP, FMR LLC, Artal Group S.A., Geode Capital Management LLC, Geode Capital Management LLC, Two Sigma Advisers LP and Rhumbline Advisers. Company insiders that have bought Selecta Biosciences stock in the last two years include Amir Nashat, Earl Sands, Timothy A Springer, Timothy C Barabe and Werner Cautreels. View Insider Buying and Selling for Selecta Biosciences.
How do I buy shares of Selecta Biosciences?
Shares of SELB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Selecta Biosciences' stock price today?
One share of SELB stock can currently be purchased for approximately $2.58.
How big of a company is Selecta Biosciences?
Selecta Biosciences has a market capitalization of $57.98 million and generates $900,000.00 in revenue each year. The company earns $-65,340,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis.
What is Selecta Biosciences' official website?
How can I contact Selecta Biosciences?
Selecta Biosciences' mailing address is 480 Arsenal Way, Watertown MA, 02472. The company can be reached via phone at 617-923-1400 or via email at [email protected]
MarketBeat Community Rating for Selecta Biosciences (NASDAQ SELB)
MarketBeat's community ratings are surveys of what our community members think about Selecta Biosciences and other stocks. Vote "Outperform" if you believe SELB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SELB will underperform the S&P 500 over the long term. You may vote once every thirty days.
